GE HealthCare's Phase 2 results support advancement of investigational manganese-based MRI contrast agent mangaciclanol into Phase 3 of LUMINA clinical trial
November 19, 2026
November 19, 2026
CHICAGO, Illinois, Nov. 19 [Category: Health Care] -- G.E. HealthCare posted the following news release:
* * *
GE HealthCare's Phase 2 results support advancement of investigational manganese-based MRI contrast agent mangaciclanol into Phase 3 of LUMINA clinical trial
*
Don't have an account?
CHALFONT ST GILES, UK -- 19 November, 2026 -- GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into . . .
* * *
GE HealthCare's Phase 2 results support advancement of investigational manganese-based MRI contrast agent mangaciclanol into Phase 3 of LUMINA clinical trial
*
Don't have an account?
CHALFONT ST GILES, UK -- 19 November, 2026 -- GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into . . .
